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Induction of Peripheral T Cell Tolerance In Vivo
Requires CTLA-4 Engagement
Victor L. Perez,*³§ Luk Van Parijs,*§ Andre Biuckians,* with higher affinity to B7 molecules, functions as a nega-
tive regulator of immune responses (Walunas et al.,Xin Xiao Zheng,² Terry B. Strom,² and Abul K. Abbas*
*Immunology Research Division 1994; Krummel and Allison, 1995). The critical role of
CTLA-4 in maintaining homeostasis in the immune sys-Department of Pathology
Brigham and Women's Hospital tem is illustrated by mice made genetically deficient
in CTLA-4. These mice develop a lymphoproliferativeand Harvard Medical School
Boston, Massachusetts 02115 disorder with autoimmune destruction of multiple tis-
sues (Tivol et al., 1995; Waterhouse et al., 1995). In vivo²Department of Medicine
Beth Israel Hospital blockade of CTLA-4 also enhances anti-tumor immunity
and exacerbates autoimmune reactions (Leach et al.,and Harvard Medical School
Boston, Massachusetts 02115 1996; Karandikar et al., 1996; Perrin et al., 1996). Thus,
T cell responses to protein antigens are regulated by
the integration of positive and negative signals that
come from surface molecules on the APCs. In these
Summary
studies, we use an in vivo model of antigen-specific T
cell tolerance that allows us to investigatethe interaction
Studies of T cell anergy in vitro have led to the widely
of these signals in the induction of peripheral T cell
accepted view that anergy is induced by T cell antigen
tolerance in vivo.recognition without costimulation. We show that the
induction of T cell anergy in vivo is due to an abortive
ResultsT cell response that requires recognition of B7 mole-
cules, since blocking B7 maintains T cells in an unacti-
Induction of Peripheral T Cellvated but functionally competent state. Furthermore,
Tolerance In Vivothe induction of anergy is prevented by blocking
To analyze the role of costimulators in tolerance induc-CTLA-4, the inhibitory T cell receptor for B7 molecules.
tion in mature CD41 helper T lymphocytes in vivo, andThus, in vivo T cell anergy may be induced not because
the fates of tolerant T cells, we have used an in vivoof a lack of costimulation, but as a result of specific
model initially described by Kearney et al. (1994). T cellsrecognition of B7 molecules by CTLA-4. In contrast,
expressing a transgenic T cell receptor (TCR), calledblocking CD28 on T cells prevents priming but not
DO11.10 (Murphy et al., 1990), specific for a known pep-the induction of tolerance. Therefore, the outcome of
tide antigen, ovalbumin (OVA)323±339 plus I-Ad, were trans-antigen recognition by T cells is determined by the
ferred into syngeneic recipients and exposed to the anti-interaction of CD28 or CTLA-4 on the T cells with B7
gen in immunogenic and tolerogenic forms. Recipientmolecules.
mice were either not immunized, given antigen in incom-
plete Freund's adjuvant (IFA) subcutaneously, which in-
Introduction duces a functional response in T cells in the draining
lymph nodes, or treated with a large dose of antigen
The activation of mature T lymphocytes requires antigen intraperitoneally, which induces tolerance in these same
recognition and additional signals, collectively called lymph node cells (Kearney et al., 1994). We chose to
costimulation. Antigen recognition alone is believed to use IFA as the adjuvant in order to minimize local inflam-
induce a state of unresponsiveness known as anergy mation, which might bias the subsequentT cell response
(Schwartz, 1990; Mueller et al., 1989). This concept, toward T helper type 1 (Th1) dominance. All of the mice
which is based in large part on studies with cloned cell were challenged with immunogenic antigen 10 days
lines, has provided the rationale for numerous attempts later, and after 3 days lymph node cells were recovered
to induce tolerance in vivo, e.g., against transplanted and analyzed by staining and functional assays. Viable
tissues and self-antigens (Lenschow et al., 1992; Miller T cells expressing the DO11.10 TCR were readily de-
and Flavell, 1994). However, the mechanisms of T cell tected in all groups by staining with the clonotypic anti-
anergy in vivo are not well defined. Furthermore, recent TCR antibody, KJ-126 (Haskins et al., 1983). The total
data indicate that costimulation is more complex than numbers of DO11.10 T cells recovered from lymph
originally thought, because costimulators can deliver nodes of tolerized mice were significantly less (2.0 6
both activating and inhibitory signals (Jenkins, 1994; 0.1 3 105; average of six mice from two experiments)
Linsley, 1995). The engagement of the CD28 receptor than from immunized animals (6.1 6 0.4 3 105; average
on T cells by B7 molecules on the surface of antigen- of six mice from two experiments). Lymph node cells
presenting cells (APCs) provides an activating signal. In harvested from mice primed with antigen subcutane-
contrast, CTLA-4 (CD152),a homolog of CD28 that binds ously (immunogenic antigen) showed strong prolifer-
ative responses to the antigen in vitro, and secreted
interleukin-2 (IL-2) and the effector cytokine, inter-³Present address: Schepens Eye Research Instituteand Massachu-
feron-g (IFNg) (Figure 1). In this experiment, all micesetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard
were challenged with antigen prior to harvest, and thisMedical School, Boston, Massachusetts 02114.
§These two authors have contributed equally to the work. is why mice that did or did not receive a priming dose
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Figure 1. Induction of Peripheral T Cell Tolerance In Vivo Is Characterized by the Inability of T Cells to Produce IL-2 and Differentiate into
IFNg-Producing Effector Cells upon Challenge with Immunogenic Antigen
Balb/c recipients of DO11.10 T cells were treated with no antigen (A; naive, triangles), OVA323±339 peptide in adjuvant subcutaneously (B; primed,
squares), or antigen intraperitoneally (C; tolerized, circles). All mice were challenged with antigen in adjuvant subcutaneously on day 10, and
lymph node cells were harvested 3 days later. Cells were stained for FACS analysis, and restimulated with antigen in culture to measure
proliferation and cytokine production. One representative experiment of four is shown, using 2±3 mice per group, and standard deviations
are shown from duplicate samples of each measurement.
of antigen (groups A and B) showed similar T cell re- administration (without an in vivo challenge) and restim-
ulated in vitro. This analysis revealed that the cells couldsponses to restimulation with antigen in vitro. In con-
trast, prior administration of antigen intraperitoneally be classified into three functional groups (Figure 2). Na-
ive T cells (not exposed to antigen in vivo) produced(tolerogenic antigen) significantly reduced the ability of
the T cells to proliferate and prevented secretion of IL-2 IL-2 with a peak at day 3, proliferated modestly, and
did not produce IFNg. Primed T cells, from mice givenand IFNg (Figure 1). The block in T cell proliferation is
seen even when data are expressed as cpm per culture. antigen subcutaneously, showed stronger proliferative
responses, produced larger amounts of IL-2 with anFor instance, in this experiment, 5 3 105 lymph node
cells stimulated with 0.01 mg/ml of peptide for 3 days early peak (day 1), and secreted IFNg, reflective of their
differentiation into Th1 cells. In contrast, T cells fromshowed the following [3H]TdR incorporation: group A,
696,085 6 23,228 cpm; group B, 314,197 6 26,883 cpm; mice given tolerogenic antigen in vivo did not produce
IL-2 or IFNg and showed essentially no proliferation.group C, 48,127 6 1,306 cpm. We have chosen to ex-
press the data as proliferation per input T cell because Similar unresponsiveness was also induced by intrave-
nous injection of 300 mg of aqueous peptide antigenthis corrects for differences in cell expansion and recov-
ery. Identical results were obtained when mice were (data not shown). We generally get more consistent tol-
erance induction with peptide in IFA administered intra-primed with complete Freund's adjuvant or were toler-
ized by intravenous injection of 300 mg of aqueous pep- peritoneally, and this is the protocol we have used for
the subsequent experiments. These results suggestedtide antigen (data not shown). Tolerogenic antigen did
not induce cell death, because functionally unrespon- that T cells rendered tolerant in vivo may be distin-
guished from naive (unstimulated) cells on the basis ofsive antigen-specific T cells were detectable in lymph
nodes even 10±14 days after exposure to the tolerogenic functional responses.
antigen (Figure 1). Furthermore, tolerogenic forms of an-
tigen did not promote differentiation of the T cells toward Tolerogenic Antigen Induces an Abortive,
Costimulation-Dependentthe Th2 phenotype, as assessed by IL-4, IL-5, and IL-
10 assays (data not shown). T Cell Response
We next asked whether the induction of anergy wasTo determine whether functional unresponsiveness
was induced rapidly after the administration of tolero- associated with any phenotypic changes in antigen-spe-
cific T cells, i.e., do T cells show detectable responsesgen, the same adoptive transfer system was used, but
cells were harvested only 3±4 days after initial antigen to tolerogenic antigens. To do this, DO11.10 transfer
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Figure 2. Tolerogenic Antigen Induces a
Population of T Cells That Is Functionally Dis-
tinguishable from Naive and Primed Cells
Lymph node cells collected from mice of na-
ive (triangle), primed (squares), and tolerized
(circles) groups, 3 days after antigen adminis-
tration, were restimulated with antigen in
vitro.Proliferation was corrected for KJ-1261/
CD41 cells, and IL-2 and IFNg production
were assayed. One experiment of four is
shown, using 2±3 mice per group, and stan-
dard deviations are shown from duplicate
samples of each measurement.
recipients were left untreated, primed or tolerized, and even tolerogenic antigen is recognized with costimula-
tors and, in fact, that the induction of T cell tolerancecells were harvested 3 days later and stained for the
expression of activation markers on the antigen-specific may require some level of costimulation. To test this
possibility, mice that had received DO11.10 T cells were(KJ-1261/CD41) cells. T cells from tolerized mice showed
an increase in cell size and decreased expression of exposed in vivo to tolerogenic antigen alone or together
with murine CTLA-4±immunoglobulin (CTLA-4±Ig) fusionCD45RB, and were phenotypically indistinguishable
from cells harvested from primed animals (Figure 3). protein, to block theB7 family of costimulators (Freeman
et al., 1993; Linsley et al., 1992). Flow cytometric analysisThese activation markers induced by both immunogenic
and tolerogenic forms of antigen are typically seen in T of DO11.10 T cells harvested 3 days later showed that
T cells exposed to tolerogenic antigen plus CTLA-4±Igcells that have encountered both antigen and costimula-
tion (Kearney et al., 1995). This raised the possibility that exhibited the phenotype of unstimulated cells, i.e.,
Figure 3. Tolerogenic Antigen Induces Phe-
notypic Changes Associated with Activation
in Antigen-Specific T Cells, Which Are Pre-
vented by Blocking Costimulation
DO11.10 T cells were adoptively transferred
intounirradiated syngeneic Balb/c recipients,
treated with no antigen (A; naive), OVA323±339
peptide in IFA subcutaneously (B; primed),
OVA323±339 peptide in IFA intraperitoneally plus
a mouse IgG2a antibody control (C; tolerized
plus immunoglobulin control), and OVA323±339
peptide in IFA intraperitoneally plus murine
CTLA-4±Ig fusion protein (D; tolerized plus
CTLA-4±Ig). Cells harvested 3 days later were
stained and examined for size and CD45RB
expression gating on the antigen-specific KJ-
1261/CD41 lymphocytes. The results are rep-
resentative of four experiments with 2±3 mice
per group.
Immunity
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Figure 5. Blocking B7 Prevents Tolerance Induction and Maintains
Responsiveness to Antigen Challenge In Vivo
Mice were treated initially as in Figure 4 and challenged with
OVA323±339 peptide in IFA subcutaneously on day 10. Lymph node
cells were harvested 3 days later and assayed for proliferation in
response to antigen restimulation in vitro. Results from two experi-
ments are shown.
members. It is knownthat the initiation and maintenance
of a full T cell response to antigen requires recognition
of B7 molecules on APCs by CD28 on the T cells (Boise
Figure 4. Blocking B7-Mediated Costimulation Prevents Tolerance et al., 1995; Lucas et al., 1995). Since the induction of
Induction and Maintains Antigen-Specific T Cells in a Functionally
anergy also appears to be dependent on B7, we postu-Competent State
lated that anergy is induced if T cells engage B7 byDO11.10 transfer recipients were treated with no antigen (A; naive,
the inhibitory receptor, CTLA-4. To test this hypothesis,triangles), OVA323±339 peptide in IFA intraperitoneally plus immuno-
mice that had received DO11.10 T cells were left un-globulin control (B; tolerized plus mIgG control, circles), and
OVA323±339 peptide in IFA intraperitoneally plus murine CTLA-4±Ig treated or exposed to immunogenic (subcutaneous) an-
fusion protein (C; tolerized plus CTLA-4±Ig, crosses). Lymph node tigen or tolerogenic (intraperitoneal) antigen alone or
cells were harvested 3 days after antigen was administered and with anti-CTLA-4 monoclonal antibody (MAb) treatment.
restimulated in vitro with antigen. Proliferation and IL-2 secretion are
T cells from all groups of mice were harvested after 3shown. One representative experiment of four is shown; standard
days (without additional antigen challenge) and restimu-deviations were calculated from duplicate samples of each mea-
lated with antigen in culture. As shown in Figure 6, naivesurement.
T cells (not exposed to antigen in vivo) produced IL-2
with a peak at zday 3, proliferated modestly, and did
not produce IFNg. Primed T cells, from mice given anti-they were small in size and CD45RBhigh (Figure 3D).
Thus, blocking B7 molecules prevented the phenotypic gen subcutaneously, showed stronger proliferative re-
sponses, produced larger amounts of IL-2 with an earlychanges associated with tolerance induction.
To determine whether the inductionof functional unre- peak (zday 1), and secreted IFNg. Tolerized T cells,
from mice given antigen intraperitoneally, did not pro-sponsiveness was also B7-dependent, mice were given
tolerogenic antigen and CTLA-4±Ig or control immuno- duce IL-2 or IFNg and did not proliferate. Strikingly, cells
from mice given tolerogenic antigen plus anti-CTLA-4globulin, and cells wereharvested 3 days later. As shown
in Figure 4, blocking B7 molecules prevented the block MAb showed strong proliferative responses, produced
significant amounts of IL-2, and were now able to se-in proliferation and IL-2 production induced by tolero-
genic antigen. Thus, day 3 IL-2 levels in T cells from crete the effector cytokine, IFNg, as well. Thus, blocking
CTLA-4 during the initial response to tolerogenic antigenmice tolerized with peptide (group B) or tolerized and
treated with CTLA-4±Ig (group C) were significantly dif- protected antigen-specific T cell from becoming anergic
and promoted their differentiation into effector cells.ferent by t test (p , 0.001). This was also seen when
mice given tolerogenic antigen with or without CTLA- These results raised the possibility that the response
of T cells depends on whether they utilize CD28 or4±Ig were challenged with antigen 10 days later and
assayed 3 days after challenge. Again, CTLA-4±Ig CTLA-4 to recognize costimulators. To test this, recipi-
ents of DO11.10 T cells were primed or tolerized astreatment during administration of tolerogen prevented
functional inactivation of the T cells, as measured by before and treated with anti-CD28 or control antibody.
Blocking CD28 almost completely blocked priming byantigen-induced proliferation (Figure 5). In none of the
antigen-treated groups did we detect Th2 cytokines antigen given subcutaneously, but had no effect on tol-
erance induction, in striking contrast with the result of(IL-4, IL-5, or IL-10) upon in vitro restimulation (data not
shown). blocking CTLA-4 (Figure 7).
DiscussionThe Induction of T Cell Tolerance Requires
CTLA-4 Engagement
The unexpected conclusion of these experiments is that The results in this paper demonstrate that the induction
of anergy in CD41 T lymphocytes in vivo has two unex-immunological tolerance in vivo is due to an active T
cell response that requires costimulation by B7 family pected features. First, the induction of anergy requires
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Figure 6. Blocking CTLA-4 Engagement with
Anti-CTLA-4 MAb In Vivo Prevents the Induc-
tion of T Cell Tolerance
DO11.10 transfer recipients were treated with
noantigen (A; naive, triangles), OVA323±339 pep-
tide in adjuvant subcutaneously (B; primed,
squares), OVA323±339 peptide in IFA intraperito-
neally (C; tolerized, circles), and OVA323±339
peptide in IFA intraperitoneally plus anti-
CTLA-4 MAb (13) (D; tolerized plus CTLA-4
antibody,stars). Cells were harvested and as-
sayed as in Figures 2 and 4. A controlhamster
IgG antibody does not have any effect on the
induction of tolerance (data not shown).
costimulation by B7 molecules. In the absence of B7, T cell molecule mayaccount for theautoimmune disease
that develops in CTLA-4 knockout mice (Tivol et al.,e.g., in mice treated with the B7 antagonist, CTLA-4±Ig,
tolerogenic antigen does not lead to functional inactiva- 1995; Waterhouse et al., 1995). This role of CTLA-4 in
tolerance induction contrasts with the obligatory role oftion, and the T cells retain the phenotype of unstimulated
cells. This is a form of clonal ignorance that is best CD28 in T cell priming in vivo (Figure 7). An important
question that emerges is why immunogenic forms ofstudied in vivo using cells from TCR transgenic mice,
because responses of these T cells can be followed and antigens are recognized by T cells in the context of
CD28±B7 interactions, whereas tolerogenic antigensareeasily assayed. In vitro, antigen-specific T cells appear
to down-regulate survival genes rapidly and undergo recognized along with CTLA-4±B7 interactions. This
question is difficult toanswer because it is not yet possi-programmed cell death when cultured with antigen in
the absence of costimulation (Van Parijs et al., 1996). ble to identify the APCs that present immunogenic and
tolerogenic proteins to antigen-specific T cells in vivo.In contrast with clonal ignorance, functional anergy is
induced by an abortive, B7-dependent T cell response. Our results suggest that there are distinct conse-
quences of antigen recognition by T cells, which areThis suggests that the concept that T cell tolerance is
due to a lack of costimulation, which is based on in vitro likely determined by the level and duration of costimula-
tion. In the complete absence of costimulation, T cellsstudies with cell lines (Schwartz, 1990; Mueller et al.,
1989), may not be applicable to the in vivo situation. will not be stimulated via CD28 (or CTLA-4) and will not
respond to antigen. This will be manifested by ªigno-Studies of the effects of B7 antagonists on allograft
rejection or T cell±dependent immune responses have ranceº in vivo (Ohashi et al., 1991) and programmed cell
death in vitro (Van Parijs et al., 1996). This is the outcomeshown blocks in activation that are often interpreted as
tolerance induction (Linsley et al., 1992; Lin et al., 1993). of antigen recognition in mice given tolerogenic antigen
(Figures 4 and 5) or immunogenic antigen (Kearney etHowever, in these studies, T cells may remain function-
ally capable of responding to antigen, i.e., they are not al., 1995) in the presence of a B7 antagonist, e.g., CTLA-
4±Ig. With low levels of costimulation for brief periods,rendered anergic (Lenschow et al., 1995). Furthermore,
if B7±CD28 interactions are blocked with CTLA-4±Ig 2 the T cells may preferentially engage B7 by the high
affinity receptor, CTLA-4, and become anergic; this maydays after transplantation, graft survival is significantly
prolonged compared with groups that received CTLA- happen with systemic antigen administration without
strong adjuvants. Blocking CTLA-4 may prevent an ªoffº4±Ig on the day of engraftment (Sayegh et al., 1995).
This is consistent with our view that antigen recognition signal that is required for T cell anergy, or itmay enhance
the production of growth factors that prevent or reversewith initial costimulation enhances functional anergy.
The second major conclusion of these studies is that anergy (Kearney et al., 1995). This occurs in mice treated
with tolerogenic antigen in the presence of an antibodythe induction of T cell anergy requires an interaction
between CTLA-4 on the T cells and B7 molecules on to CTLA-4, which prevents anergy induction (Figure 6).
In contrast, higher levels and more prolonged expres-APCs (Figure 6). Thus, the finding that a B7 antagonist
blocks tolerance can now be explained by the require- sion of B7 molecules may lead to sustained engagement
of CD28, and a normal T cell response, which would bement for CTLA-4 engagement for inducing tolerance.
The obligatory role of CTLA-4 as a tolerance-inducing dependent on CD28-mediated signals (Figure 7). It is,
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our pathogen-free facilities (VAF) in accordance with the guidelines
of the Committee on Animals of the Harvard Medical School and
those prepared by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Resources, National Research
Council (DHEW Publication [NIH] FS-23).
Adoptive Transfers and Immunizations
DO11.10 TCR transgenic lymph node and spleen cells were pre-
pared as previously described (Perez et al., 1994) and injected intra-
venously into unirradiated syngeneic Balb/c recipients, such that
each received z5 3 106 naive KJ-1261/CD41 T cells. At 2 days
after transfer, animals were untreated (naive group) or immunized
subcutaneously with 30 mg of the OVA323±339 peptide emulsified in
IFA (Difco, Detroit, MI; primed group) or intraperitoneally with 300
mg of the peptide emulsified in IFA (tolerized group). For in vivo
challenge experiments, all the mice were immunized 10 days later
in the footpad with 30 mg of OVA323±339 peptide in IFA, and cells from
draining lymph nodes (inguinal and popliteal) were harvested 3 days
later. For the early timepoint experiments, cells were harvested from
axillary, inguinal, and popliteal lymph nodes cells 3 days after anti-
gen administration.
In Vivo Antibody Treatments
In vivo administration of murine CTLA-4±Ig (Steurer et al., 1995) and
mouse IgG2a antibody control (Cappel, Durham, NC; 200 mg per
animal intraperitoneally) or anti-CTLA-4 MAb, UC-410 (75 mg per
animal intraperitoneally; Pharmingen, San Diego, CA), anti-CD28
(100 mg per animal intraperitoneally; courtesy of Dr. J. Allison, Uni-
versity of California, Berkeley), and hamster immunoglobulin anti-
body control (100 mg per animal intraperitoneally; courtesy of Dr.
A. Sharpe, Harvard Medical School, Boston, MA) was done on days
21, 0, and 11 of initial exposure to antigen.
Flow Cytometry
Peripheral lymph node cells were harvested, and 1 3 106 cells were
Figure 7. In Vivo Blocking of CD28 Prevents T Cell Responses to incubated with anit-CD4-PE (Pharmingen), the biotinylated KJ-126
Immunogenic Antigen, but Does Not Affect the Induction of T Cell MAb (Haskins et al., 1983), followed by streptavidin±FITC (Phar-
Tolerance mingen). After washing, cells were fixed with 1% paraformaldehyde
DO11.10 transfer recipients were treated with no antigen (A; naive, andanalyzed on a Becton Dickinson FACScan. For three-color stain-
triangles), OVA323±339 peptide in adjuvant subcutaneously plus control ing, cells were incubated with anti-CD4-Cy-chrome (Pharmingen),
hamster IgG antibody (B; primed plus control antibody, squares), FITC-labeled KJ-126 MAb, and anti-CD45RB-PE (Pharmingen) for
OVA323±339 peptide in adjuvant subcutaneously plus anti-CD28 anti- 30 min at 48C, washed, and fixed. FACS analysis was done from
body (C; primed plus anti-CD28, circles), OVA323±339 peptide in IFA 50,000 collected events. Analysis of activation marker expression
intraperitoneally plus control hamster IgG antibody (D; tolerized, and cell size (FSC, forward scatter) was performed by gating on the
crosses), and OVA323±339 peptide in IFA intraperitoneally plus anti- KJ-1261/CD41 population.
CD28 antibody (D; tolerized plus anti-CD28, stars). Cells were har-
vested and assayed as in Figures 2 and 4. In Vitro Cultures and Assays of Proliferation
and Cytokine Production
In vitro proliferative responses to antigen were measured by cultur-
ing 5 3 105 lymph node cells with OVA323±339 peptide antigen in 200of course, possible that factors other than the level and
ml for 48 hr in RPMI-1640 medium (CellGrow) supplemented with
duration of costimulator expression, such as the nature 10% fetal calf serum, 1 mM L-glutamine, streptomycin±penicillin,
of the APCs, may determine whether CD28 or CTLA-4 nonessential amino acids, sodium pyruvate, HEPES (all from GIBCO
Laboratories), and5 3 1025 M 2-mercaptoethanol. Cells were pulsedis preferentially engaged. Furthermore, the relationship
with 1 mCi of [3H]thymidine (New England Nuclear) for the final 6 hrbetween these two receptors for B7 molecules is also
and then harvested for liquid scintillation counting. The number ofcomplex, because some in vitro studies indicate that
KJ-1261 cells per culture was calculated by multiplying the fre-the expression of CTLA-4 is itself dependent on CD28-
quency of KJ-1261 cells in each cell population by the number of
mediated signals (Walunas et al., 1996; Krummel and cells per well (5 3 105 cells). The mean cpm from each group was
Allison, 1996). Nevertheless, our results suggest that then divided by this number. Cytokine production was measured
from 1 ml cultures containing 2 3 106 lymph node cells, which wereoptimal strategies for inducing T cell activation or toler-
stimulated with no antigen or 1 mg/ml OVA323±339 peptide. Cultureance may require fine controls on the nature, level, and
supernatants were collected on days 1±3, and IL-2 and IFNg levelsduration of costimulation at the time of antigen recogni-
were determined using ELISA (Pharmingen).tion, along with regulating the balance between CD28-
and CTLA-4-triggered signals. Acknowledgments
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